Researchers at Tel Aviv University have identified a significant link between damaging variants in innate immunity genes and earlier breast cancer (BC) onset in carriers of the BRCA1 mutation. Through whole exome sequencing of Ashkenazi Jewish women with the BRCA1 risk variant, the study revealed that variants affecting natural killer (NK) cell activation were most strongly associated with an earlier diagnosis of breast cancer.
This discovery suggests that the current understanding of risk among BRCA1 carriers may need refinement, as the age of diagnosis varies widely despite the high lifetime risk of breast cancer associated with the mutation. The authors propose that personalized risk prediction models could enhance clinical decision-making for these patients, particularly regarding preventative surgical options.
Published in the Journal of Medical Genetics, the study emphasizes the potential role of innate immune pathways as modifiers of breast cancer risk in BRCA1 carriers. The findings call for further investigation into the implications of immune function on cancer development and highlight the necessity for larger, ethnically diverse studies to validate these preliminary results.
Get started today with Solo access →
